Wouter Lansink
Overview
Explore the profile of Wouter Lansink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deloose K, Gielis J, Maene L, Lansink W, Lerut P, Verbist J, et al.
J Cardiovasc Surg (Torino)
. 2025 Jan;
66(1):37-45.
PMID: 39878064
Background: Due to the heterogeneity of literature findings, stent type selection for the endovascular treatment of complex aorto-iliac occlusive disease remains challenging. The BELSTREAM study, a physician-initiated, prospective, multicenter, single-arm...
2.
Deloose K, Lansink W, Brodmann M, Werner M, Keirse K, Goueffic Y, et al.
JACC Cardiovasc Interv
. 2023 Dec;
16(23):2900-2914.
PMID: 38092496
Background: There is a scarcity of published head-to-head comparisons between different paclitaxel-coated angioplasty balloons. More prospective safety data to support the health care economic reimbursement processes are needed. Objectives: The...
3.
Deloose K, Lansink W, Brodmann M, Werner M, Keirse K, Goueffic Y, et al.
Cardiovasc Intervent Radiol
. 2022 Sep;
45(12):1855-1859.
PMID: 36058996
Purpose: Although effectiveness and safety of many different paclitaxel coated balloons in the treatment of peripheral arterial disease (PAD) are extensively studied, there is a lack of direct head-to-head comparison...
4.
Brodmann M, Lansink W, Guetl K, Micari A, Menk J, Zeller T
Cardiovasc Intervent Radiol
. 2022 Jul;
45(9):1276-1287.
PMID: 35864209
Purpose: Data on the long-term safety and effectiveness of drug-coated balloons (DCBs) for the treatment of long femoropopliteal atherosclerotic lesions in the real-world setting are rare. This study reports 3 ...
5.
Bosiers M, Deloose K, Callaert J, Verbist J, Hendriks J, Lauwers P, et al.
J Cardiovasc Surg (Torino)
. 2020 Nov;
61(5):617-625.
PMID: 33231029
Background: This clinical trial aims to evaluate the outcome (up to 24-months) of the treatment of in-stent restenotic or reoccluded lesions in the femoropopliteal arteries, by comparing the treatment of...
6.
Nauwelaers S, Lansink W, Schroe H, Lauwers G
J Vasc Access
. 2019 Jul;
21(1):105-109.
PMID: 31328635
Non-maturation of arteriovenous fistulas is a frequent problem after dialysis access creation, especially in the forearm. The presence of accessory veins may play an important role in the non-maturing fistula....
7.
Lammer J, Bosiers M, Deloose K, Schmidt A, Zeller T, Wolf F, et al.
JACC Cardiovasc Interv
. 2016 Jun;
9(11):1178-87.
PMID: 27282601
Objectives: This is the first-in-human study of a drug-eluting bioresorbable vascular scaffold (BVS) for treatment of peripheral artery disease (PAD) involving the external iliac artery (EIA) and superficial femoral artery...
8.
Bosiers M, Deloose K, Callaert J, Verbist J, Hendriks J, Lauwers P, et al.
J Endovasc Ther
. 2015 Mar;
22(1):1-10.
PMID: 25775672
Purpose: To evaluate the short- and midterm outcomes of the Viabahn endoprosthesis with Propaten Bioactive Surface vs. standard balloon angioplasty for treatment of in-stent restenosis in the superficial femoral artery....
9.
Bosiers M, Deloose K, Verbist J, Schroe H, Lauwers G, Lansink W, et al.
J Vasc Surg
. 2006 Feb;
43(2):313-8.
PMID: 16476607
Objective: Several prosthetic materials have been used for femoropopliteal bypass grafting in patients with peripheral vascular disease in whom a venous bypass is not possible. Expanded polytetrafluoroethylene (ePTFE) is the...